JP2016510749A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510749A5
JP2016510749A5 JP2015561621A JP2015561621A JP2016510749A5 JP 2016510749 A5 JP2016510749 A5 JP 2016510749A5 JP 2015561621 A JP2015561621 A JP 2015561621A JP 2015561621 A JP2015561621 A JP 2015561621A JP 2016510749 A5 JP2016510749 A5 JP 2016510749A5
Authority
JP
Japan
Prior art keywords
salt
solvate
compound
bacterial infection
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015561621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510749A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/020910 external-priority patent/WO2014138302A1/en
Publication of JP2016510749A publication Critical patent/JP2016510749A/ja
Publication of JP2016510749A5 publication Critical patent/JP2016510749A5/ja
Ceased legal-status Critical Current

Links

JP2015561621A 2013-03-05 2014-03-05 キナゾリノン抗生物質 Ceased JP2016510749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361851310P 2013-03-05 2013-03-05
US61/851,310 2013-03-05
PCT/US2014/020910 WO2014138302A1 (en) 2013-03-05 2014-03-05 Quinazolinone antibiotics

Publications (2)

Publication Number Publication Date
JP2016510749A JP2016510749A (ja) 2016-04-11
JP2016510749A5 true JP2016510749A5 (enExample) 2017-04-06

Family

ID=51491923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561621A Ceased JP2016510749A (ja) 2013-03-05 2014-03-05 キナゾリノン抗生物質

Country Status (4)

Country Link
US (2) US9776975B2 (enExample)
EP (1) EP2964618B1 (enExample)
JP (1) JP2016510749A (enExample)
WO (1) WO2014138302A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111434775B (zh) * 2019-01-11 2022-12-06 上海医药工业研究院 一种发酵制备达托霉素的方法
CN110437162B (zh) * 2019-07-09 2021-01-05 贵州医科大学 一种含环羟肟酸的化合物及其制备方法和应用
US11648248B1 (en) 2022-01-12 2023-05-16 King Abdulaziz University Potent antimicrobial compounds with a pyridazine nucleus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
JPH01110677A (ja) 1987-10-23 1989-04-27 Asahi Chem Ind Co Ltd 新規キナゾリノン化合物およびその製造方法
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
AU2006311883A1 (en) 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
WO2009082398A1 (en) 2007-12-21 2009-07-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
EP2285831A4 (en) 2008-05-07 2011-05-04 Innovative Biosensors Inc REAGENTS, METHODS, AND SYSTEMS FOR DETECTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS (MRSA)
US8263642B2 (en) * 2008-06-25 2012-09-11 Vanderbilt University Antimicrobial compounds and methods of use thereof
MX2011002185A (es) 2008-08-28 2011-04-04 Astrazeneca Ab Composiciones y metodos de tratamiento que comprenden ceftarolina.
EP2691542A4 (en) * 2011-03-29 2014-12-24 Trana Discovery Inc SCREENING PROCEDURE FOR IDENTIFICATION OF SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS

Similar Documents

Publication Publication Date Title
Charles et al. The dearth of new antibiotic development: why we should be worried and what we can do about it
TWI327573B (en) 6-11 bicyclic ketolide derivatives
CA2818100C (en) Compounds and their use
US20200093814A1 (en) Combination therapy with amidine substituted beta-lactam compounds and beta-lactamase inhibitors for infections with antibiotic resistant bacterial strains
UA96964C2 (ru) Соединения полициклической мочевины с антибактериальными свойствами
RU2015138796A (ru) Способы и составы для лечения респираторных заболеваний
WO2009140215A3 (en) Method for treating drug-resistant bacterial and other infections with clioquinol, phanquinone, and related compounds
HRP20130928T1 (hr) C7-fluor supstituirani spojevi tetraciklina
JP6480870B2 (ja) 細菌感染を処置するための組成物および方法
WO2011160020A3 (en) Carbapenem antibacterials with gram-negative activity
JP2016510749A5 (enExample)
NZ706734A (en) Pharmaceutical compositions useful for the treatment or control of bacterial infections
JP2024009968A5 (enExample)
WO2006063039A3 (en) 3, 6-bicyclolides
WO2006039263A3 (en) NOVEL BICYCLIC 9a-AZALIDE DERIVATIVES
WO2009124086A3 (en) Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
WO2006065721A3 (en) 11, 12-lactone bicyclolides
WO2007098868A8 (en) Use of moxifloxacin in combination with cefixime for treatment of infectious diseases caused by gram-positive and gram-negative pathogens
Cattoir et al. Quelles nouveautés en antibiothérapie?
TW200635600A (en) Tetracyclic bicyclolides
WO2008014221A3 (en) Bridged carbamate macrolides
WO2007044927A3 (en) 6, 11-bridged tricyclic macrolides
WO2007017762A3 (en) Phosphonated fluoroquinolones, antibacterial analogs thereof, and methods for the prevention and treatment of bone and joint infections
UA94177C2 (en) antimicrobial composition
JP6178224B2 (ja) 併用抗メチシリン耐性黄色ブドウ球菌薬、及びβラクタム系抗生物質の抗菌活性増強剤